Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis). According to ...

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III drugs for Myasthenia Gravis have a 70% phase ...

Analysts at Jefferies have previously said that iptacopan could hit $3.6 billion in peak annual sales if it gets approved for all its target indications, which along with PNH include atypical ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

目前没有 Fabhalta 仿制药。Iptacopan 仅以 Fabhalta 品牌出售。Fabhalta 于 2023 年 12 月 5 日获得 FDA 批准，用于治疗 PNH。2024 年 8 月 8 日，FDA 批准范围根据加速审批规定延长，将患有 IgAN 且有病情进展风险的成年人纳入其中。Fabhalta 是否能继续获批用于治疗 IgAN 取决于 ...

These advances are making it easier to manage C3G as well as help quality life with fewer interventions for patients. Iptacopan is a novel oral drug being developed for the treatment of Complement 3 ...

Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures CG64 17 March 2008 8 July 2016 ...

Bupropion hydrochloride is a generic prescription drug used for depression and seasonal affective disorder. Bupropion comes as oral tablets. Bupropion, also called bupropion hydrochloride ...

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

Participants treated with endothelin (receptor) antagonists within 90 days prior to first study drug administration. * Prior use of iptacopan (LNP023) or prior enrollment in any other LNP023 clinical ...